Unlicensed medicines use: a UK guideline analysis using AGREE II

Objectives There is widespread use of unlicensed medicines within primary and secondary care but little information is available around how these medicines are used. This analysis examines and evaluates the content and quality of relevant guidance documentation currently in use within the UK. Method...

Full description

Saved in:
Bibliographic Details
Published in:The International journal of pharmacy practice 2018-12, Vol.26 (6), p.515-525
Main Authors: Donovan, Gemma, Parkin, Lindsay, Brierley‐Jones, Lyn, Wilkes, Scott
Format: Article
Language:English
Subjects:
Drug Approval
evidence based practice
Guidelines
Humans
interface issues
interprofessional issues
Medicine
patient safety
Pharmaceutical Preparations - administration & dosage
Pharmacy
Practice Guidelines as Topic
Practice Patterns, Physicians' - standards
Research Paper
Research Papers
United Kingdom
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives There is widespread use of unlicensed medicines within primary and secondary care but little information is available around how these medicines are used. This analysis examines and evaluates the content and quality of relevant guidance documentation currently in use within the UK. Methods Guidance documents were identified through a literature search as well as email requests to pharmacy organisations throughout the UK. Unlicensed medicine documentation suitable for inclusion in the analysis underwent thematic analysis and quality assessment using the AGREE II tool. Key findings Thematic analysis of 52 guidelines revealed four parent themes: (1) Professional responsibility (2) Usage practicalities (3) Risk versus benefit (4) Controlling use. There was variability in scores across the AGREE II domains with areas covering Scope and Purpose and Clarity of Presentation scoring well. Conversely, an area needing attention was Rigour of Development. Conclusion Healthcare organisations would benefit from agreeing a ‘core content’ for the development of unlicensed medicines guidelines to ensure consistency and the presence of robust operating systems to deliver safe, effective treatment to all NHS patients.
ISSN:0961-7671
2042-7174
DOI:10.1111/ijpp.12436